We narrowed the list to 202 stocks with dividend yields of at least 4%. Then we cut the list to 176 companies covered by at least five analysts working for brokerages or research firms polled by LSEG.

BME’s portfolio is a who’s-who of medical-device makers. What’s more, Becton Dickinson is not a top-10 holding (it’s No. 16, ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 ...

Pfizer ( ($PFE) ) has provided an announcement. On December 16, 2025, Pfizer announced its financial guidance for the full year 2026, while ...

Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...

Becton Dickinson and Co, iShares U.S. Pharmaceuticals ETF, BlackRock Health Sciences Trust. Read 's Market Analysis on Investing.com ...

However, both companies are likely to survive their current headwinds and thrive over the long term. If you are willing to ...

Pfizer shares managed to close the trading week with modest gains, but any investor relief is likely to be fleeting. Market attention is now fixed on a pivot ...

Wondering if Pfizer is quietly turning into a value opportunity, or if the market is still too skeptical, you are not alone.